111.16
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$109.27
Offen:
$110
24-Stunden-Volumen:
6.04M
Relative Volume:
0.80
Marktkapitalisierung:
$138.43B
Einnahmen:
$28.75B
Nettoeinkommen (Verlust:
$480.00M
KGV:
300.43
EPS:
0.37
Netto-Cashflow:
$10.31B
1W Leistung:
+5.00%
1M Leistung:
-0.74%
6M Leistung:
+32.95%
1J Leistung:
+52.25%
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
GILD
Gilead Sciences Inc
|
111.16 | 138.43B | 28.75B | 480.00M | 10.31B | 0.37 |
![]()
LLY
Lilly Eli Co
|
821.67 | 738.00B | 45.04B | 10.59B | 414.30M | 11.71 |
![]()
ABBV
Abbvie Inc
|
202.72 | 358.61B | 56.33B | 4.28B | 17.83B | 2.40 |
![]()
JNJ
Johnson Johnson
|
163.13 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
![]()
NVO
Novo Nordisk Adr
|
70.16 | 311.44B | 42.09B | 14.65B | 10.11B | 3.2833 |
![]()
MRK
Merck Co Inc
|
87.60 | 221.28B | 64.17B | 17.12B | 18.10B | 6.73 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-04 | Bestätigt | Oppenheimer | Outperform |
2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2024-12-10 | Fortgesetzt | BofA Securities | Buy |
2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
2024-11-14 | Eingeleitet | Citigroup | Buy |
2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2024-10-17 | Eingeleitet | Bernstein | Outperform |
2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2024-05-01 | Bestätigt | Maxim Group | Buy |
2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
2024-02-22 | Herabstufung | Truist | Buy → Hold |
2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
2023-07-24 | Bestätigt | Barclays | Equal Weight |
2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
2022-10-28 | Bestätigt | Cowen | Outperform |
2022-10-28 | Bestätigt | JP Morgan | Overweight |
2022-10-28 | Bestätigt | Jefferies | Buy |
2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
2022-10-28 | Hochstufung | Truist | Hold → Buy |
2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
2022-02-02 | Bestätigt | BofA Securities | Neutral |
2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
2022-02-02 | Bestätigt | Truist | Hold |
2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
2022-01-28 | Hochstufung | Argus | Hold → Buy |
2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
2021-12-06 | Eingeleitet | Goldman | Neutral |
2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
2021-10-20 | Fortgesetzt | Cowen | Outperform |
2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2020-10-28 | Eingeleitet | UBS | Neutral |
2020-09-30 | Fortgesetzt | Jefferies | Buy |
2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
2020-07-31 | Bestätigt | Credit Suisse | Neutral |
2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
2020-07-31 | Bestätigt | Piper Sandler | Overweight |
2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
2020-07-31 | Bestätigt | SunTrust | Hold |
2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
2020-04-27 | Herabstufung | UBS | Buy → Neutral |
2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead to Expand R&D in China to Accelerate Access to Antiviral Treatments, Local GM Says - Yicai Global
Gilead Sciences CEO's pay climbed to $23.7 million - The Business Journals
Gilead Says CEO Daniel O'Day's 2024 Total Compensation Was $23.7 MillionSEC Filing - Marketscreener.com
What Analysts Are Saying About Gilead Sciences Stock - Benzinga
A Closer Look at Gilead Sciences's Options Market Dynamics - Benzinga
JPMorgan Adjusts Price Target on Gilead Sciences to $130 From $120, Maintains Overweight Rating - Marketscreener.com
Potential federal budget cuts won't rock Gilead's HIV boat too much: analysts - FiercePharma
Gilead’s HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise. - Barron's
Are Medical Stocks Lagging Gilead Sciences (GILD) This Year? - Yahoo Finance
Gilead price tries to regain footingForecast today26-03-2025 - Economies.com
Former Gilead Sciences VP Named CEO as Biomea Advances Breakthrough Diabetes Drug - StockTitan
Gilead, J&J Sue Laurus Labs to Block Copy of HIV Drug Complera - Bloomberg Law
Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer - ACCESS Newswire
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
The Inner Circle acknowledges, Christopher McCormick as a Pinnacle Professional Member Inner Circle of Excellence - Yahoo Finance
Gilead Sees Success With HIV PrEP Trial In South Africa - Clinical Leader
Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval - Seeking Alpha
Gilead Sciences Inc (GILD) Shares Up 1.14% on Mar 22 - GuruFocus.com
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences Inc (GILD) - GuruFocus.com
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed - Benzinga
Gilead Sciences Inc (GILD) Stock Price Up 0.52% on Mar 21 - GuruFocus.com
Gilead Sciences stock performance analysis: A rare Nasdaq gem with consistent returns across time horizons - The Financial Express
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
GILD Stock Down on Report of Cut in HIV Prevention Spending - Yahoo Finance
Oppenheimer doesn’t see threat to Gilead estimates after HHS plans for HIV cuts - Yahoo Finance
Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed - MSN
Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides - Yahoo Finance
Gilead Stock Falls on Report U.S. Could Slash HIV-Prevention Budget - The Wall Street Journal
Gilead stock falls on report of HIV prevention cuts - Yahoo Finance
Gilead Stock Dives On A Devastating Potential Call From HHS - Investor's Business Daily
Stock of the Day: Gilead Sciences falls on report the Trump administration could slash funds for HIV prevention - Yahoo Finance
Wall Street weighs in on Gilead as shares fall on possible U.S. HIV cuts - Investing.com Canada
BMO reiterates Gilead stock with $115 target amid HIV funding concerns - Investing.com
Citi maintains Gilead stock Buy rating, $125 target amid HIV funding fears - Investing.com
Gilead Sciences Should Not See Any Impact From HIV-Related Cost Reductions at US Healthcare Department, Truist Says - Marketscreener.com
Gilead Sciences Ranked in Top Five Most JUST List for Biopharma Companies - CSRwire.com
Gilead Sciences’ SWOT analysis: HIV giant’s stock faces pivotal transition - Investing.com
Gilead Sciences Stock Slips on Possible HIV Funding Cut - Schaeffers Research
Why Gilead Sciences (GILD) Is Among the Most Undervalued Biotech Stocks to Invest In - Insider Monkey
Citi Defending Gilead Sciences (GILD): 'we are buyers of GILD stock on any weakness ahead of the upcoming Len PrEP launch in mid-2025' - StreetInsider.com
Gilead Stock Falls on Report Trump Administration Wants to Cut HIV-Prevention Funding - Barron's
Gilead Stock (NYSE:GILD) Slumps on HIV Funding Cuts Report - TipRanks
Gilead slides as Trump administration puts HIV prevention funds under review - TradingView
Gilead Sciences (GILD): Potential Impact of Federal HIV Funding Cuts - Value the Markets
Gilead, GSK could be impacted by potential HHS HIV prevention cuts - Seeking Alpha
Gilead Sciences CFO Andrew Dickinson sells $276,325 in stock - Investing.com
After-hours movers: Gilead Sciences, HealthEquity, CARGO Therapeutics and more - Investing.com
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):